Kaoru Toyama

1.0k total citations
34 papers, 817 citations indexed

About

Kaoru Toyama is a scholar working on Molecular Biology, Genetics and Epidemiology. According to data from OpenAlex, Kaoru Toyama has authored 34 papers receiving a total of 817 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Genetics and 5 papers in Epidemiology. Recurrent topics in Kaoru Toyama's work include Influenza Virus Research Studies (5 papers), Bone Metabolism and Diseases (4 papers) and Pain Management and Opioid Use (3 papers). Kaoru Toyama is often cited by papers focused on Influenza Virus Research Studies (5 papers), Bone Metabolism and Diseases (4 papers) and Pain Management and Opioid Use (3 papers). Kaoru Toyama collaborates with scholars based in Japan, Germany and United Kingdom. Kaoru Toyama's co-authors include Tetsu Akiyama, Hiroshi Takano, Morihisa Hirota, Yumi Kanegae, Izumu Saito, Kiyotaka Shiba, Tetsuo Noda, Masaki Ito, Sumitaka Hasegawa and Hiroshi Matsumoto and has published in prestigious journals such as Science, International Journal of Molecular Sciences and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Kaoru Toyama

32 papers receiving 790 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kaoru Toyama Japan 10 500 233 166 153 123 34 817
Kerstin Enquist Sweden 15 476 1.0× 227 1.0× 117 0.7× 141 0.9× 384 3.1× 18 868
K Nelson United States 8 487 1.0× 146 0.6× 168 1.0× 155 1.0× 81 0.7× 10 776
Aytekin Akyol Türkiye 14 464 0.9× 313 1.3× 154 0.9× 181 1.2× 151 1.2× 40 964
Chongjuan Wei United States 17 516 1.0× 237 1.0× 70 0.4× 212 1.4× 171 1.4× 34 919
Lyle E. Pegg United States 11 431 0.9× 162 0.7× 103 0.6× 153 1.0× 78 0.6× 17 873
Marta I. Gallego Spain 13 434 0.9× 435 1.9× 171 1.0× 47 0.3× 116 0.9× 19 829
Wei‐Yu Lin Taiwan 16 350 0.7× 123 0.5× 111 0.7× 111 0.7× 116 0.9× 44 667
F. Alameda Spain 13 312 0.6× 268 1.2× 93 0.6× 66 0.4× 117 1.0× 28 711
Sharon Amir Israel 12 340 0.7× 107 0.5× 70 0.4× 146 1.0× 228 1.9× 17 636
G Emilion United Kingdom 15 350 0.7× 232 1.0× 112 0.7× 112 0.7× 139 1.1× 16 763

Countries citing papers authored by Kaoru Toyama

Since Specialization
Citations

This map shows the geographic impact of Kaoru Toyama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaoru Toyama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaoru Toyama more than expected).

Fields of papers citing papers by Kaoru Toyama

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaoru Toyama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaoru Toyama. The network helps show where Kaoru Toyama may publish in the future.

Co-authorship network of co-authors of Kaoru Toyama

This figure shows the co-authorship network connecting the top 25 collaborators of Kaoru Toyama. A scholar is included among the top collaborators of Kaoru Toyama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaoru Toyama. Kaoru Toyama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Toyama, Kaoru, et al.. (2023). Pharmacokinetics and Bioequivalence of Mirogabalin Orally Disintegrating Tablets and Conventional Tablets in Healthy Japanese Participants. Clinical Pharmacology in Drug Development. 12(10). 985–990. 1 indexed citations
2.
Tachibana, Masaya, et al.. (2023). Safety, Tolerability, and Pharmacokinetics of Valemetostat Tablets and the Effect of Food on Valemetostat Pharmacokinetics in Healthy Subjects: Two Phase 1 Studies. Clinical Pharmacology in Drug Development. 13(1). 77–86. 12 indexed citations
3.
Li, Yi, Kaoru Toyama, Hitoshi Ishizuka, et al.. (2023). Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study. Advances in Therapy. 40(4). 1628–1643. 4 indexed citations
4.
Toyama, Kaoru, Takashi Eto, Kenji Takazawa, et al.. (2023). DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study. Vaccine. 41(38). 5525–5534. 9 indexed citations
5.
Shiosakai, Kazuhito, Tatsuya Hashimoto, Takaaki Akasaka, et al.. (2022). Steady-State Pharmacokinetics of Intravenous Hydromorphone in Japanese Patients With Renal Impairment and Cancer Pain. Journal of Palliative Medicine. 26(6). 768–775. 2 indexed citations
6.
Toyama, Kaoru, Hidetoshi Furuie, Tomoko Ishizuka, et al.. (2021). Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males. European Journal of Drug Metabolism and Pharmacokinetics. 46(5). 685–694. 2 indexed citations
7.
Ishizuka, Hitoshi, Hidetoshi Furuie, & Kaoru Toyama. (2018). Intrapulmonary pharmacokinetics of laninamivir in healthy subjects: Comparison between a nebulizer and a dry powder inhaler. PA5454–PA5454. 2 indexed citations
8.
9.
Toyama, Kaoru, Hidetoshi Furuie, & Hitoshi Ishizuka. (2017). Safety and Pharmacokinetics of Nebulized Laninamivir Octanoate, A Long Acting Neuraminidase Inhibitor, In Healthy Subjects. Clinical Therapeutics. 39(8). e25–e26. 3 indexed citations
10.
Toyama, Kaoru, Naoki Uchida, Hitoshi Ishizuka, Takehiko Sambe, & Shinichi Kobayashi. (2015). Single‐dose evaluation of safety, tolerability and pharmacokinetics of newly formulated hydromorphone immediate‐release and hydrophilic matrix extended‐release tablets in healthy Japanese subjects without co‐administration of an opioid antagonist. The Journal of Clinical Pharmacology. 55(9). 975–984. 9 indexed citations
11.
12.
Kohno, Takashi, Hideo Kunitoh, Kaoru Toyama, et al.. (2006). Association of the OGG1‐Ser326Cys polymorphism with lung adenocarcinoma risk. Cancer Science. 97(8). 724–728. 66 indexed citations
13.
Kohno, Takashi, Tokuki Sakiyama, Hideo Kunitoh, et al.. (2006). Association of polymorphisms in the MTH1 gene with small cell lung carcinoma risk. Carcinogenesis. 27(12). 2448–2454. 25 indexed citations
14.
Kasuga, Ikuma, David T. Miyamoto, Yukito Ichinose, et al.. (1998). Alpha-fetoprotein producing pulmonary blastoma in a patient with systemic sclerosis: pathogenetic analysis. European Respiratory Journal. 11(5). 1185–1187. 7 indexed citations
15.
Ohyashiki, Kazuma, et al.. (1997). Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia. 11(2). 190–194. 77 indexed citations
16.
Ohyashiki, Kazuma, J H Ohyashiki, Naoyuki Yahata, & Kaoru Toyama. (1997). 144 Detection of telomerase activity in cell in myelodysplastic syndromes: Application of in situ telomeric repeat amplification protocol (TRAP). Leukemia Research. 21(1). S37–S37.
17.
Moriyama, Nobuo, et al.. (1991). Urethral Adenocarcinoma with High Levels of CA19‐9 in Serum and Tumour Specimen. British Journal of Urology. 67(2). 220–221. 1 indexed citations
18.
Akazawa, Shoichi, et al.. (1985). Radioimmunoassay of human plasma apolipoprotein A-1: pretreatment of plasma with guanidine hydrochloride.. PubMed. 12(6). 388–98. 4 indexed citations
19.
Dziedzic-Gocławska, A., K. Ostrowski, R Moutier, Kaoru Toyama, & H Lamendin. (1978). Induction of heterotopic bone marrow formation in osteopetrotic rats by allogeneic decalcified bone matrix.. PubMed. 26(1-6). 1041–6. 1 indexed citations
20.
Lamendin, H, R Moutier, & Kaoru Toyama. (1976). Odontogenic Proliferation After Parabiosis in Phenotype : OP Rats. Journal of Dental Research. 55(2). 313–313. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kerstin Enquist Breakdown of academic impact, for papers by K Nelson Breakdown of academic impact, for papers by Aytekin Akyol Breakdown of academic impact, for papers by Chongjuan Wei Breakdown of academic impact, for papers by Lyle E. Pegg Breakdown of academic impact, for papers by Marta I. Gallego Breakdown of academic impact, for papers by Wei‐Yu Lin Breakdown of academic impact, for papers by F. Alameda Breakdown of academic impact, for papers by Sharon Amir Breakdown of academic impact, for papers by G Emilion
Rankless by CCL
2026